Novel agents in Hodgkin lymphoma.
Despite the success of modern therapy for Hodgkin lymphoma (HL), about 15 % of patients will fail both first-line and second-line therapy and treatment options for these patients are limited. New agents are needed to improve the outcome for relapsed or refractory HL and to improve the toxicity of current front-line regimens. Brentuximab vedotin (BV) was recently approved for HL and is likely to have a tremendous impact on the current treatment paradigm for HL. Additional agents that have demonstrated activity in HL include histone deacetylase inhibitors, such as panobinostat, entinostat, and mocetinostat, PI3-kinase/Akt/Mtor pathway inhibitors, such as everolimus, as well as lenalidomide and bendamustine. Studies evaluating these agents alone or in combination with either chemotherapy or other targeted agents are ongoing. Current challenges in HL research include identifying the most appropriate drug combinations of new and old drugs and identifying predictors of response to the new targeted agents.
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. moskowia@mskcc.org
Alison J
AJ
Moskowitz
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D000079963:Brentuximab Vedotin; D000068338:Everolimus; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000077269:Lenalidomide; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D018796:Immunoconjugates; D009588:Nitrogen Mustard Compounds; D047428:Protein Kinase Inhibitors; D013792:Thalidomide; C401859:temsirolimus; D000079963:Brentuximab Vedotin; D000069461:Bendamustine Hydrochloride; D000068338:Everolimus; D000077269:Lenalidomide; D020123:Sirolimus